France
· Delayed Price · Currency is EUR Transgene Company Description
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases.
It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors.
The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox.
The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
| Country | France |
| Founded | 1979 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Alessandro Riva |
Contact Details
Address: 400, boulevard Gonthier d’Andernach Illkirch-Graffenstaden France | |
| Phone | 33 3 88 27 91 00 |
Stock Details
| Ticker Symbol | TNG |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0005175080 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alessandro Riva M.D. | Chief Executive Officer and Chairman of the Board |
| Lucie Larguier | Chief Financial Officer |
| Dr. Maurizio Ceppi | Vice President and Chief Scientific Officer |
| John Felitti J.D., LLM | Vice President, General Counsel and Corporate Secretary |
| Christelle Schwoerer | Chief Human Resources Officer |
| James Wentworth M.B.A., Ph.D. | Vice President and Chief Business Officer |
| Emmanuelle Dochy M.D. | Vice President of Medical Affairs and Chief Medical Officer |
| Gaelle Stadtler | Vice President and Director of Human Resources |
| Kaidre Bendjama | Project Leader of Personalized Cancer Vaccines |